To Assess the Efficacy of Collagen Supplement in Osteoarthritis
Launched by VEDIC LIFESCIENCES PVT. LTD. · Jul 8, 2020
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Osteoarthritis (OA) is a chronic progressive degenerative disease involving thinning of cartilage in movable joints that leads to friction between bones creating pain, stiffness, and abnormal movement. It is estimated to affect more than 20% of the population over the age of 60 years and is considered to be a major cause of morbidity, disability, and limitations on the quality of life. In India, studies have reported the prevalence of 22% to 39%, with OA being 2nd most common rheumatological disorder. , As global life expectancy increases, the prevalence of OA is expected to rise further ul...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male \& female aged ≥ 40 to ≤ 65 years suffering from knee joint pain for at least 3 months prior to screening.
- • BMI ≥ 18.5 and ≤ 29.9 kg/m2.
- • Non-vegetarians (Regardless of whether they eat chicken, fish, goat mutton, pork, beef or eggs).
- • Screening Visual Analogue (VAS) scores for knee joint pain ≥ 60 on a 100-point scale.
- • Radiographic evidence of grade II/III knee OA based on one of following criteria.
- • Participants willing to stop the restricted supplements and medications prior to inclusion and throughout the study period.
- • Participants willing to stop any home-based remedies or any other form of topical products intended for knee joint pain relief or any other reason for the entire study duration.
- • Willing to stop the use of study designated rescue medication 48 hours prior to all assessment visits.
- • Willing to abstain from food containing type II collagen only from cartilage, e.g. chicken, fish, beef, pork, etc. 48 hours prior to all assessment visits.
- Exclusion Criteria:
- • Prior or ongoing medical conditions (e.g. concomitant illness, psychiatric disorders, etc.), abnormal medical history or physical findings.
- • Participants with history of type II diabetes and uncontrolled hypertension.
- • Fasting Blood glucose \> 125 mg/dl
- • Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
- • Radiographic evidence of Grade I or Grade IV OA based on the KL radiographic criteria for osteoarthritis.
- • Any history of trauma, fractures or surgery to the index joint.
- • Any planned surgery (diagnostic or therapeutic intervention) to the index joint during the participation in the study.
- • Participants with deformity of the knee joint.
- • Participants with a diagnosed condition which may involve or involves the index joint that includes but is not limited to known rheumatic or inflammatory conditions such as rheumatoid arthritis, osteomyelitis, osteoporosis, gout, and bone metastasis.
- • Other pathologic lesions on X-rays of the knee.
- • Current smokers or chronic alcoholics
About Vedic Lifesciences Pvt. Ltd.
Vedic Lifesciences Pvt. Ltd. is a leading clinical research organization based in India, dedicated to providing comprehensive services in clinical trial management and pharmaceutical development. With a strong focus on quality and innovation, Vedic Lifesciences supports the healthcare industry by facilitating the successful conduct of clinical trials across various therapeutic areas. The organization is committed to adhering to international regulatory standards and employs a team of experienced professionals to ensure the integrity and efficacy of clinical data. Through strategic partnerships and a client-centric approach, Vedic Lifesciences aims to accelerate the development of new therapies and enhance patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Navi Mumbai, Maharashtra, India
Mumbai, Maharashtra, India
Mumbai, Maharashtra, India
Mumbai, Maharashtra, India
Varanasi, Uttar Pradesh, India
Patients applied
Trial Officials
Dr. Shalini Srivastava, MD - Med.
Study Director
Vedic Life Sciences Pvt. Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials